- Home
- JUNS vs ELDN Comparison
JUNS vs ELDN Comparison
Compare JUNS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- ELDN
- Stock Information
- Founded
- JUNS 2015
- ELDN 2004
- Country
- JUNS United States
- ELDN United States
- Employees
- JUNS N/A
- ELDN N/A
- Industry
- JUNS
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- ELDN Health Care
- Exchange
- JUNS NYSE
- ELDN Nasdaq
- Market Cap
- JUNS 281.4M
- ELDN 288.5M
- IPO Year
- JUNS 2024
- ELDN N/A
- Fundamental
- Price
- JUNS $0.84
- ELDN $4.29
- Analyst Decision
- JUNS
- ELDN Strong Buy
- Analyst Count
- JUNS 0
- ELDN 1
- Target Price
- JUNS N/A
- ELDN $16.00
- AVG Volume (30 Days)
- JUNS 602.5K
- ELDN 232.7K
- Earning Date
- JUNS 03-04-2025
- ELDN 03-27-2025
- Dividend Yield
- JUNS N/A
- ELDN N/A
- EPS Growth
- JUNS N/A
- ELDN N/A
- EPS
- JUNS N/A
- ELDN N/A
- Revenue
- JUNS N/A
- ELDN N/A
- Revenue This Year
- JUNS N/A
- ELDN N/A
- Revenue Next Year
- JUNS N/A
- ELDN N/A
- P/E Ratio
- JUNS N/A
- ELDN N/A
- Revenue Growth
- JUNS N/A
- ELDN N/A
- 52 Week Low
- JUNS $0.78
- ELDN $1.52
- 52 Week High
- JUNS $19.51
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- ELDN 44.28
- Support Level
- JUNS N/A
- ELDN $4.40
- Resistance Level
- JUNS N/A
- ELDN $4.65
- Average True Range (ATR)
- JUNS 0.00
- ELDN 0.23
- MACD
- JUNS 0.00
- ELDN -0.04
- Stochastic Oscillator
- JUNS 0.00
- ELDN 8.16
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.